128 related articles for article (PubMed ID: 12003186)
41. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
Ratain MJ; Mick R; Janisch L; Berezin F; Schilsky RL; Vogelzang NJ; Kut M
Pharmacogenetics; 1996 Feb; 6(1):93-101. PubMed ID: 8845865
[TBL] [Abstract][Full Text] [Related]
42. Phase II study of Didemnin B in central nervous system tumors: a Southwest Oncology Group study.
Taylor SA; Giroux DJ; Jaeckle KA; Panella TJ; Dakhil SR; Schold SC
Invest New Drugs; 1998-1999; 16(4):331-2. PubMed ID: 10426666
[TBL] [Abstract][Full Text] [Related]
43. Amonafide in metastatic colorectal carcinoma.
Scheithauer W; Kornek G; Haider K; Depisch D
Eur J Cancer; 1990; 26(8):923-4. PubMed ID: 2145944
[No Abstract] [Full Text] [Related]
44. Phase II study of Mitonafide in advanced and relapsed colorectal cancer.
Abad A; Grávalos C; Font A; Molina F; Díaz-Puente MT; Fabregat X; Benavides A; Martín M
Invest New Drugs; 1996; 14(2):223-5. PubMed ID: 8913845
[TBL] [Abstract][Full Text] [Related]
45. A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer.
Witte RS; Hsieh P; Elson P; Oken MM; Trump DL
Invest New Drugs; 1996; 14(4):409-13. PubMed ID: 9157078
[TBL] [Abstract][Full Text] [Related]
46. Clinical pharmacokinetics of amonafide (NSC 308847) in 62 patients.
Kreis W; Chan K; Budman DR; Allen SL; Fusco D; Mittelman A; Hock K; Akerman S; Calabro A; Puccio C; Spigelman M
Cancer Invest; 1996; 14(4):320-7. PubMed ID: 8689426
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic characterization of mitonafide in man.
Brode E; Poveda Velasco A; Díaz-Rubio E; Rosell Costa R; Benavides Fissure A
Methods Find Exp Clin Pharmacol; 1992 Mar; 14(2):131-40. PubMed ID: 1598025
[TBL] [Abstract][Full Text] [Related]
48. Phase I clinical investigation of benzisoquinolinedione.
Legha SS; Ring S; Raber M; Felder TB; Newman RA; Krakoff IH
Cancer Treat Rep; 1987 Dec; 71(12):1165-9. PubMed ID: 3690526
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans.
Felder TB; McLean MA; Vestal ML; Lu K; Farquhar D; Legha SS; Shah R; Newman RA
Drug Metab Dispos; 1987; 15(6):773-8. PubMed ID: 2893701
[TBL] [Abstract][Full Text] [Related]
50. Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer.
Rosell R; Carles J; Abad A; Ribelles N; Barnadas A; Benavides A; Martin M
Invest New Drugs; 1992 Aug; 10(3):171-5. PubMed ID: 1330970
[TBL] [Abstract][Full Text] [Related]
51. In vitro activity of amonafide against primary human tumors compared with the activity of standard agents.
Ajani JA; Baker FL; Spitzer G
Invest New Drugs; 1988 Jun; 6(2):79-85. PubMed ID: 3170133
[TBL] [Abstract][Full Text] [Related]
52. Statistical method for evaluation of dissolution stability in the formulation development of solid dosage forms: tablets of amonafide.
Gil-Alegre ME; Bernabeu JA; Camacho MA; Torres-Suarez AI
Pharmazie; 2004 Jul; 59(7):541-7. PubMed ID: 15296092
[TBL] [Abstract][Full Text] [Related]
53. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
Ratain MJ; Rosner G; Allen SL; Costanza M; Van Echo DA; Henderson IC; Schilsky RL
J Clin Oncol; 1995 Mar; 13(3):741-7. PubMed ID: 7884434
[TBL] [Abstract][Full Text] [Related]
54. Paradoxical relationship between acetylator phenotype and amonafide toxicity.
Ratain MJ; Mick R; Berezin F; Janisch L; Schilsky RL; Williams SF; Smiddy J
Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):573-9. PubMed ID: 1934870
[TBL] [Abstract][Full Text] [Related]
55. Pharmaceutical development of tablets of a new antineoplastic drug: mitonafide.
Torres Suárez AI; Gil Alegre ME; Camacho Sánchez MA
Pharm Acta Helv; 1994 Oct; 69(2):101-5. PubMed ID: 7809172
[TBL] [Abstract][Full Text] [Related]
56. Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage.
De Isabella P; Zunino F; Capranico G
Nucleic Acids Res; 1995 Jan; 23(2):223-9. PubMed ID: 7862525
[TBL] [Abstract][Full Text] [Related]
57. Comparative analysis of xanafide cytotoxicity in breast cancer cell lines.
Alami N; Paterson J; Belanger S; Juste S; Grieshaber CK; Leyland-Jones B
Br J Cancer; 2007 Jul; 97(1):58-64. PubMed ID: 17551498
[TBL] [Abstract][Full Text] [Related]
58. Correspondence re: Mark J. Ratain et al., Limited Sampling Models for Amonafide (NSC 308847) Pharmacokinetics.
Lemmer B
Cancer Res; 1989 Jun; 49(11):3139-40. PubMed ID: 2720672
[No Abstract] [Full Text] [Related]
59. Qualitative and quantitative determination of two new antitumor agents from 1-8 naphthalimides in tablets. Validation of a high performance liquid chromatography method.
Camacho MA; Torres AI; Gil ME; Obregón MM; Ruz V
Arzneimittelforschung; 1994 May; 44(5):659-62. PubMed ID: 8024643
[TBL] [Abstract][Full Text] [Related]
60. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.
Costanza ME; Weiss RB; Henderson IC; Norton L; Berry DA; Cirrincione C; Winer E; Wood WC; Frei E; McIntyre OR; Schilsky RL
J Clin Oncol; 1999 May; 17(5):1397-406. PubMed ID: 10334524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
